Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
- NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Studyon June 30, 2022 at 7:06 pm
CAMBRIDGE, Mass., June 30, 2022. NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC,...
- Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856on June 29, 2022 at 7:06 pm
STOCKHOLM, June 29, 2022. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's...
- DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumorson June 29, 2022 at 4:06 am
BOSTON. June 29, 2022 --DermBiont, a clinical-stage biotechnology company announced today positive results meeting primary and secondary endpoints in a Phase 2 clinical trial with a topical formulation of investigational drug SM-020, a specific...
- Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myelomaon June 29, 2022 at 2:06 am
June 29, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the...
- Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasison June 28, 2022 at 8:06 pm
PRINCETON, N.J., June 28, 2022. Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that...
- Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticityon June 28, 2022 at 4:06 am
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results...
- NIH Scientists Identify New Brain Mechanism Involved in Impulsive Cocaine-Seeking in Ratson June 28, 2022 at 3:06 am
Discovery may represent a future target for treating substance use disorders. June 28, 2022 -- Researchers have found that blocking certain acetylcholine receptors in the lateral habenula (LHb), an area of the brain that balances reward and...
- Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupuson June 28, 2022 at 3:06 am
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is...
- Basilea Announces Positive Results of Phase 3 ERADICATE Study with Ceftobiprole in Staphylococcus Aureus Bacteremia (SAB)on June 28, 2022 at 3:06 am
Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Basel, Switzerland, June 28, 2022 -- Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage...
- Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Diseaseon June 27, 2022 at 7:06 pm
TOKYO, June 26, 2022. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the US Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence...
- Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicronon June 25, 2022 at 12:06 am
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a...
- Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease modelon June 24, 2022 at 11:06 am
Denmark, June 24, 2022 - Saniona a clinical stage biopharmaceutical company, today announced that professor Helle Prætorius, Univ. of Aarhus, Denmark, made a presentation at the ECM conference, 2022, which shows that SAN903 protects...
- Sanofi-GSK First to Report a Successful Efficacy Study Against Omicron with COVID-19 Beta-Containing Vaccineon June 24, 2022 at 1:06 am
Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic infection in adults, and 75.1% efficacy in participants previously infected with COVID-19 Against Omicron, sequencing analysis performed to...
- Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Doseon June 24, 2022 at 1:06 am
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose...
- Researchers Find That a Japanese Medicinal Mushroom Extract Can Help the Body Clear Persistent HPV Infectionson June 23, 2022 at 2:06 pm
NEW YORK, June 22, 2022. According to a paper published in Frontiers in Oncology, daily use of a unique mushroom extract AHCC supported the immune system in clearing HPV infections in two-thirds of study participants after six months of...
- ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilisation from Tissues, Potentially Closing Treatment Gaps for Wilson Disease Communityon June 23, 2022 at 2:06 am
FoCus Phase III trial evaluates new approach to copper mobilisation for patients with Wilson disease who have not seen meaningful innovation in decades In Wilson disease, excess copper build-up in organs and tissues can lead to liver disease as...
- Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weekson June 23, 2022 at 1:06 am
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 23, 2022-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex (bulevirtide) for the...
- Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5on June 22, 2022 at 11:06 pm
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study Data Being Submitted to Regulators and for Peer Reviewed Publication CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022...
- First Subject Dosed in Phase 1b Clinical Trial of Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adultson June 22, 2022 at 2:06 pm
MADISON, Wis., June 22, 2022. FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the dosing of its first subject in an unprecedented study of older adults ages 65-85...
- Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)on June 21, 2022 at 10:06 pm
New Drug Application filing anticipated based on positive data from interim analysis 21 June 2022 -- Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid...